AUTH/2606/5/13: General Practitioner v Takeda — Prostap meeting Q&A (no breach) | PMCPA Case

📊

Key facts

⌄

Case number	AUTH/2606/5/13
Complainant	General practitioner
Company	Takeda UK Ltd
Product	Prostap (leuprorelin acetate); formulation referenced: Prostap 3 DCS
Setting	Takeda-sponsored meeting (“An Update on Prostate Cancer”), May 2013
Core allegation	Speaker said route of administration “did not matter” (intramuscular vs subcutaneous), implying promotion outside the licence; Takeda representative did not comment
Takeda’s position	Answer was consistent with the licence; speaker/chair accounts aligned; no need for representative intervention
Panel decision	No breach; complainant did not establish allegation on balance of probabilities
Clauses considered	2, 3.2, 9.1
Outcome	No breach of Clauses 3.2, 9.1, or 2
Complaint received	23 May 2013
Case completed	23 July 2013
Applicable Code year	2012
Appeal	No appeal

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

🎬 Expert Video Walkthrough

🎬

Video walkthrough — coming for members

Subscribe now and get expert video analysis for every case as we publish them.

Subscribe — from £299/yr

📋

⌄

A general practitioner complained about promotion of Prostap (leuprorelin acetate) at a Takeda UK-sponsored meeting (“An Update on Prostate Cancer”, May 2013).
A delegate asked about different licensed routes of administration (intramuscular in some cases, subcutaneous in others).
The complainant alleged the speaker replied that it did not matter which route was used, and that Takeda representatives did not intervene.
Takeda said it organised and funded the meeting for GPs and NHS Commissioners; it was chaired by an external consultant and the presentation was delivered by a health professional acting as a consultant to Takeda.
Takeda obtained recollections from the speaker, chairman and attending representatives; their accounts were consistent that the answer aligned with the licence and emphasised following the licensed route.
The speaker’s slides did not refer to any particular injection route.

⚖️

⌄

No breach of the Code was ruled.
No breach of Clause 3.2 (promotion outside the marketing authorisation) because the complainant did not establish the allegation on the balance of probabilities.
Consequently, no breach of Clauses 9.1 and 2.
No appeal.

🔒

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access